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Metastatic Mediastinal Germ-Cell
Tumor and Concurrent COVID-19:
When Chemotherapy Is Not Deferrable
Nappi and colleagues recently reported the viewpoints of
53 highly experienced practitioners regarding the manage-
ment of patients with germ-cell tumors (GCTs) during the
COVID-19 pandemic [1]. In this survey, the authors recom-
mend that “chemotherapy should be withheld until an active
COVID-19 infection has resolved or has been ruled out with
highly accurate molecular testing.”
Here, we report the case of a young man diagnosed with
a metastatic mediastinal GCT who received chemotherapy
despite persistent SARS-CoV-2 positivity (Fig. 1).
In March 2020, this 29-year-old patient underwent mag-
netic resonance, which revealed a lumbar spinal mass with
spinal cord invasion. Following loss of sensibility in both lower
limbs, palliative neurosurgery was performed, with histological
diagnosis of seminoma (placental alkaline phosphatase, CD117
+, CD30−, alpha-fetoprotein [αFP]−, Ki67: 80%). Serum beta-
human chorionic gonadotropin (βHCG) was undetectable,
whereas αFP and lactate dehydrogenase (LDH) were elevated
(117 ng/mL; 580 U/L), suggesting nonseminoma. The com-
puted tomography (CT) scan showed a tumor mass of
9.4 × 6.2 × 10 cm in the anterior mediastinum, with superior
vena cava compression. The testicles had no evidence of dis-
ease and the SARS-CoV-2 nasopharyngeal swab was negative.
Given the poor-risk features [2], chemotherapy with
the VIP regimen was commenced (etoposide 75 mg/m2,
ifosfamide 1,200 mg/m2, cisplatin 20 mg/m2, days 1–5, every
21 days). VIP was preferred to BEP (bleomycin, etoposide,
cisplatin) to limit the contacts with the health care system
and to avoid bleomycin pulmonary toxicity. Prophylactic
filgrastim was administered for 7 days.
After cycle 1, the patient developed transient high fever,
conjunctivitis, dysgeusia, and anosmia and tested positive
for SARS-CoV-2. Blood tests revealed lymphocytopenia and
elevation of C-reactive protein, transaminases, and LDH.
He was hospitalized and treated with hydroxychloroquine,
darunavir, and enoxaparin, with complete resolution of
symptoms. However, two swabs before cycle 2 were positive
for SARS-CoV-2.
To ensure optimal treatment delivery, cycle 2 was admin-
istered on April 14, and hydroxychloroquine was adminis-
tered on days 1–7. αFP decreased to 20 ng/mL. The restaging
CT scan revealed significant tumor response at the mediasti-
nal and lumbar levels. However, atypical, basal pneumonia
was compatible with COVID-19 (Fig. 2).
Despite this finding, cycle 3 was administered and hydro-
xychloroquine was discontinued owing to suggested useless-
ness. Swabs were performed on May 19 (negative) and May
20 (positive). Finally, two serial swabs tested negative and
SARS-CoV-2–specific immunoglobulin G (DiaSorin, Saluggia,
Italy) were detected.
The additional cycle 4 was administered on June 2. αFP,
βHCG, and LDH were normal. A leukapheresis procedure was
performed, with the successful collection of CD34+ cells for
subsequent high-dose chemotherapy [3], and the patient
underwent another intervention of spinal stabilization.
Figure 1. Laboratory parameters at diagnosis and during treatment.
Abbreviations: AFP, alpha-fetoprotein; AU, arbitrary units; Ct, cycle threshold; IgG, immunoglobulin G; N, negative; P, positive;
PBSC, peripheral blood stem cells; VIP, etoposide, ifosfamide, cisplatin.
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The SARS-CoV-2 viral loads in nasopharyngeal swabs
were retrospectively estimated using the cycle threshold
(Ct) method (Ctsample-Ctref). Ct values increased from 16.2
Ct (high viral load) to 36.96 Ct (low viral load) after cycle
3, suggesting that viral clearance may have occurred during
cycle 3 and that subsequent positive swabs did not repre-
sent active viral replication, but only residual RNA detec-
tion. To evaluate the presence of viable SARS-CoV-2, swabs
collected before cycle 4 were inoculated into cell cultures
(Vero-E6 cells); the cell culture method showed neither
virus isolation nor cytopathic effect, further reinforcing the
concept of complete viral clearance [4].
In conclusion, this patient with a poor-risk GCT underwent
multimodal curative treatment despite persistent COVID-19
infection. Our report reinforces the notion that chemotherapy
could be safely given in patients who need prompt interven-
tion, without necessarily worsening the course of COVID-19 [5].
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Figure 2. Radiological findings. Computed tomography (CT) scan showing the mediastinal mass at baseline (A) and after two cycles
of chemotherapy (B); CT scan performed after two cycles of chemotherapy showing interstitial pneumonia (C, D).
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